Madrigal Pharmaceuticals, Inc. (MDGL): R&D Expense
$388.52M
Year ended 2025-12-31
$490.14M
Trailing 12 months to 2026-06-30
+16.5%
3-year compound annual growth
+16.0%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $388.52M | +64.1% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $236.72M | -13.1% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $272.35M | +11.0% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $245.44M | +19.6% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $205.16M | +11.0% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $184.81M | +155.5% | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $72.32M | +184.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $25.39M | +4.1% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $24.39M | +53.1% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $15.93M | +556.4% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $2.43M | -96.4% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $68.20M | -5.1% | 2016-03-15, From 2014-01-01 |
| 2013-12-31 | $71.86M | +45.4% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $49.41M | +19.2% | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $41.46M | +3.0% | 2014-03-11, From 2011-01-01 |
| 2010-12-31 | $40.25M | -21.2% | 2013-03-14, From 2010-01-01 |
| 2009-12-31 | $51.05M | n/a | 2012-02-22, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $388.52M | +64.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $915.62M | +1.6% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $51.66M | +15.9% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $189.59M | +30.0% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $328.80M | +8.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $607.16M | +20.0% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
Compare MDGL, IONS, ANIP, HRMY side by side · Screen every company in Pharmaceutical Preparations ↗